Permira proposes to take Cambrex private in $2.4B deal, stirring up CDMO M&A
Cambrex is at the M&A game again, but this time it’s switching roles. After buying out Halo Pharma and Avista Pharma Solutions in the past couple of years, the contract developer and manufacturer is getting acquired.
Private equity firm Permira Funds has put a $2.4 billion offer on the table for the NYSE-listed company, which translates to $60 per share for Cambrex $CBM stockholders or a 47.1% premium to the closing price the day before. Its stock has surged on roughly the same scale.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.